HIGHLIGHTS
- who: Justinas Daraskevicius and collaborators from the Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania have published the paper: The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies, in the Journal: (JOURNAL)
SUMMARY
Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially in those undergoing hematopoietic stem_cell transplantation (HSCT). The novel oral antifungal drug of ibrexafungerp, a first-in-class triterpenoid antifungal that acts by inhibiting the glucan synthase enzyme in the fungal cell wall, was recently . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.